Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
Collegium Pharmaceutical, Inc. reports developments for a diversified biopharmaceutical business focused on commercial medicines for serious medical conditions. Its recurring news centers on JORNAY PM for ADHD, a neuropsychiatry growth business, and a responsible pain management portfolio that includes BELBUCA, Xtampza ER, Nucynta products and Symproic.
Company updates also cover operating and financial results, investor presentations, real-world data from pain medications, branded ADHD awareness campaigns, capital deployment, credit facilities, material agreements, shareholder voting matters and governance disclosures.
Collegium (Nasdaq: COLL) completed the acquisition of AZSTARYS, an ADHD treatment, from Corium Therapeutics for approximately $650 million in cash, plus up to $135 million in milestone payments. The deal is funded by $350 million cash and a $300 million term loan.
Collegium raised 2026 guidance, now expecting total product revenues, net of $865–$895 million and adjusted EBITDA of $475–$500 million, including $60–$70 million AZSTARYS revenue and >$50 million run-rate synergies within 12 months. AZSTARYS has patent protection expected through 2037. The company also announced upcoming departures of its Chief Commercial Officer and Chief Medical Officer in 2026.
Collegium (Nasdaq: COLL) reported Q1 2026 product revenues of $193.5M (up 9% YoY) and JORNAY PM net revenue of $38.9M (up 36% YoY). Adjusted EBITDA was $103.9M, GAAP net income was $14.5M, and cash, equivalents and marketable securities totaled $421.8M. The company expects to close the $650M acquisition of AZSTARYS in Q2 2026, reaffirmed full-year 2026 guidance for the current business, and scheduled a May 7, 2026 conference call.
Collegium Pharmaceutical (Nasdaq: COLL) will report first quarter 2026 financial results before the market opens on May 7, 2026. A live conference call and webcast will follow at 8:00 a.m. ET. An audio webcast will be available for replay on the company website about two hours after the event.
Collegium Pharmaceutical (Nasdaq: COLL) said management will participate in two investor events in mid-April 2026: a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference and an in-person presentation at the Piper Sandler Spring Biopharma Symposium.
The Needham fireside chat is scheduled for April 15, 2026 at 2:15 p.m. ET with a live webcast and a replay archived on the company's investor website for 90 days. Piper Sandler engagement is on April 16, 2026 in Boston.
Collegium (Nasdaq: COLL) will acquire AZSTARYS from Corium Therapeutics for $650 million in cash, with up to $135 million in contingent milestone payments. The deal is expected to close in Q2 2026, be immediately accretive to adjusted EBITDA, and deliver pro forma AZSTARYS net revenue of over $50 million in H2 2026.
Funding combines cash on hand and a $300 million delayed draw term loan; AZSTARYS is supported by patents into December 2037. Closing is subject to customary regulatory and HSR approvals.
Collegium (Nasdaq: COLL) will present two real-world data posters at PainConnect 2026, AAPM's annual meeting in Salt Lake City, March 5-8, 2026. The posters, presented March 6 on TV 1 at The Grand America Hotel, analyze buprenorphine real-world use and urine drug testing.
Presentations by Jody L. Green, PhD, highlight nonmedical use rates and presence of illicit drugs among patients treated with buprenorphine versus full agonist opioids. Important safety and approved-use information for BELBUCA (buprenorphine buccal film) is also included.
Collegium Pharmaceutical (Nasdaq: COLL) and Paris Hilton launched the "Embrace Your Sparkle" campaign on March 3, 2026 to raise awareness and destigmatize ADHD. Paris shares her personal ADHD journey and describes using JORNAY PM—an evening-dosed methylphenidate formulation—to support morning functioning and daytime symptom control.
The campaign promotes discussion with healthcare providers about individualized ADHD treatment plans and directs audiences to jornaypm.com/embrace-your-sparkle for resources.
Collegium (Nasdaq: COLL) will participate in multiple investor conferences the week of March 9–11, 2026 in Miami, FL, including Leerink Partners Global Healthcare, Jefferies Biotech on the Beach, The Citizens Life Sciences Conference, and a Barclays fireside chat on March 11 at 9:00 a.m. ET.
A live webcast of the Barclays fireside chat will be available via the Investors section of the company website and a replay will be archived for 90 days.
Collegium (Nasdaq: COLL) reported strong 2025 results: product revenues $780.6M (+24% YoY) and record quarterly revenues of $205.4M (+13% YoY). Jornay PM reached $148.9M for FY 2025 (+48% YoY) and $45.9M in the quarter (+57% YoY). Adjusted EBITDA was $460.5M (+15% YoY). The company exited 2025 with $386.7M in cash and reaffirmed 2026 guidance: Product Revenues $805–825M; Jornay PM $190–200M; Adjusted EBITDA $455–475M.
Boston Legacy FC announced a multi-year partnership with Collegium Pharmaceutical (NASDAQ: COLL) to sponsor the Collegium Sensory Room. The rooms will be available at Gillette Stadium and Centreville Bank Stadium in 2026 and at White Stadium beginning in 2027.
The sensory rooms, designed with CHADD input, provide quieter, regulated spaces for fans with sensory sensitivities and include branded signage, digital mentions, and community programming.